DePuy prices flotation in the middle of estimated range
This article was originally published in Clinica
Orthopaedics company DePuy has priced its initial public offering on the New York Stock Exchange at $17.50 a share, in the middle of the price range assumed in the prospectus. Of the 14.8 million shares offered, representing 15% of DePuy, 7.8 million were issued by the company and 7.0 million by its parent Corange, which also owns German diagnostics company Boehringer Mannheim.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.